GlaxoSmithKline PLC April 27 released its first quarter results showing a handsome payoff for a diversification policy the pharmaceutical giant implemented three years ago. Although GSK overall sales declined 11%, strong growth in emerging markets and Japan helped offset losses from key products and bolster the net profit up by 14%.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
